Login to Your Account



Interferon-Free Regimen Race Under Way

Pharmasset Launches Pivotal Phase III of PSI-7977 in HCV

By Marie Powers
Staff Writer

Wednesday, November 2, 2011

The next generation of hepatitis C virus (HCV) therapies moved a step closer to the corner drugstore with the initiation of Pharmasset Inc.'s pivotal Phase III studies of the HCV nucleotide analogue PSI-7977. The program will evaluate a 12-week, all-oral, interferon-free regimen of PSI-7977 and ribavirin in three groups of patients with HCV, independent of viral genotype or their ability to take interferon therapy.

The Princeton, N.J.-based company expects to submit data from the three Phase III trials in the second half of 2013, both in the U.S.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription